NCT03864016View on ClinicalTrials.gov

Ability of Pupillometry to Reduce Sufentanil Consumption in Planned Cardiac Surgery: Randomized, Controlled, Single-center Clinical Superiority Trial

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 20, 2019

Primary Completion Date

October 22, 2019

Study Completion Date

October 22, 2019

Conditions
Patients Undergoing Cardiac SurgeryPatients With Coronary Artery Bypass Surgery With CEC
Interventions
DRUG

Induction and maintenance of anesthesia

The hypnotic agent used is Propofol and the morphine agent used is Sufentanil.

DRUG

Adaptation of sufentanil doses according to the usual protocol

At induction the target concentration of sufentanil is 0.5 ng/ml. The sufentanil dose is decided by the anaesthetist, taking into account the operating times (induction, TIO, incision, opening and sternal spacing, CEC, closure), the usual data provided by the monitoring: heart rate, blood pressure, BIS, EtCO2, modification of insufflation pressures.

DRUG

Adjustment of sufentanil doses according to pupillometry

At induction, the target concentration of sufentanil is 0.5 ng/ml. The dose of sufentanil is then adjusted according to the dilation reflex obtained with the PPI (Pain Pupillary Index) at predefined times.

Trial Locations (1)

2100

Chu Dijon Bourgogne, Dijon

All Listed Sponsors
lead

Centre Hospitalier Universitaire Dijon

OTHER

NCT03864016 - Ability of Pupillometry to Reduce Sufentanil Consumption in Planned Cardiac Surgery: Randomized, Controlled, Single-center Clinical Superiority Trial | Biotech Hunter | Biotech Hunter